We converted Ser 207, located in helix 5 of the β 2 -adrenergic receptor, into all other natural amino acids. To quantify receptor activation as a receptor number-independent parameter and directly related to G s activation, we expressed the mutants in a Gα s -tethered form. GTP exchange in such constructs is restricted to the fused α-subunit and is a linear function of the receptor concentration. Except S207R, all other mutants were expressed to a suitable level for investigation. All mutations reduced the binding affinities of the catechol agonists, epinephrine and isoproterenol, and the extent of reduction was unrelated to the residue ability to form hydrogen bonds. Instead, both enhancements and reductions of affinity were observed for the partial agonist halostachin and the antagonist pindolol. The mutations also enhanced and diminished ligand-induced receptor activation, but the effects were strictly ligand-specific. Polar residues such as D and H exalted the activation by full agonists, but suppressed that induced by the partial agonists halostachin and dichloroisoproterenol. In contrast, hydrophobic residues such as I and V augmented partial agonist activation. Only I and K produced a significant increase of costitutive activity. The effects on binding and activity were not correlated, nor did such parameters show any clear correlation with up to 78 descriptors of amino acid physicochemical properties. Our data question the idea that S207 is exposed to the polar crevice in the unbound receptor. They also suggest that the active receptor form induced by a full agonist might be substantially different from that caused by constitutive activation.
The cluster of serines, comprising S203(5.42), S204(5.43) and S207(5.46), in H5 of the β 2 -adrenergic receptor is thought to be involved in both agonist binding and receptor activation (1) (2) (3) (4) (5) (6) (7) (8) .
Initial site-directed mutagenesis studies identified S204(5.43) and S207(5.46) as the most likely putative docking sites for catecholic hydroxyl groups of adrenergic agonists (1,2), although position 5.43 is not absolutely conserved like 5.42 and 5.46, within the subfamilies of catecholaminebinding GPCRs. More recent work (3, 4) revealed that mutagenesis of S203(5.42) can affect ligand binding and activity just like the other two serines, and suggests that all three residues may be crucial for catecholamine interaction with the β 2 AR. However, the question of how these residues may contribute to ligand-receptor interactions remains open.
Using a double alanine mutant in 5.43 and 5.46 positions (S204A,S207A) we noted that the simultaneous removal of the two residues appear to reduce the rather small constitutive activity of the β 2 AR, suggesting that the presence of the serine motif in H5 might control the intrinsic equilibrium between active and inactive receptor forms (5) . We also found that for each of the three residues the loss of binding affinity due to OH removal was inversely related to the number of additional interacting groups in the non catecholic part of the catecholamine molecule (6, 7) . This behavior suggests an "induced-fit" mechanism in catecholamine binding, such that initial contacts between ligand and receptor sub sites facilitate the establishment of the subsequent interactions. A similar scenario emerges from the analysis of catecholamine interaction with fluorophor labeled β 2 AR, where multistep kinetics was found to depend on the number of functional groups present in the catecholamine molecule (8) . A step-wise mechanism for the conversion of the β 2 AR into active form was also proposed to explain why the various functional groups in the catecholamine molecule contribute synergistically to ligand binding and receptor activation (9) .
All such evidences, along with an increasing understanding on the role of SSxxS motifs in transmembrane helices orientation (10, 11) and interactions (12) , indicate that the serine triad in H5 may play a vital role in the conformational motion of the β 2 AR.
In this study we have further investigated the contribution of H5 serines on ligand affinity and efficacy of the β 2 AR. To scan a significant range of conformational perturbations and minimize the extent of receptor modification, we replaced a single residue by all other possible amino acids. The most intramembrane of the three serines, S207(5.46), was targeted in this study.
To quantify ligand efficacy as the true intrinsic ability to drive receptor activation, without the confounding effects of changes in signaling stoichiometry, receptor trafficking, or interactions with additional effectors, all mutants were expressed as a functional receptor-Gα s fusion protein cassette. In such chimeric constructs the measurable GTPexchange response only comes from the receptortethered α-subunit (13, 14) , and the forced 1:1 stoichiometry of receptor:Gα expression makes maximal agonist stimulation a linear function of the fusion protein concentration. That corrects for the differences in expression levels. Although providing a somewhat reductive picture of the functional properties of the mutants, this approach can quantify efficacy with a precision comparable to binding affinity.
Our results suggest that the serine in position 5.46 might not be available for interaction with the catechol moiety of agonist by default, but become accessible as a consequence of conformational changes that follow initial interactions between ligand and receptor. Also, the analysis of the various functional phenotypes obtained by mutagenesis indicates that the constitutively active receptor form induced by mutagenesis might be similar to a receptor activated by partial agonist, but substantially different from the active form induced by the full agonist. Mutagenesis − The preparation of full-length cDNAs encoding the β 2 AR-Gα sL fusion protein was described previously (13) . Site-specific mutagenesis was performed by a PCR-based strategy, using mismatched primers and Pfu DNA polymerase (Stratagene). The PCR-products were digested with KpnI and EcoRV and subcloned into the pcDNA3 expression vector (Invitrogen) containing the cDNA encoding the human wild-type β 2 AR-Gα s fusion protein. Recombinant clones were isolated and the inserted mutations were confirmed by sequencing. Cell culture, transfection, and membrane preparation − COS-7 and HEK-293 cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) foetal calf serum (FCS), 100 U/ml penicillin G, and 100 µg/ml streptomycin sulphate, in a humidified atmosphere of 5% CO 2 at 37°C. Transient transfections were performed by DEAE dextran/chloroquine and calcium phosphate precipitation for COS-7 and HEK-293 cells, respectively. Enriched plasma membranes from transfected cells were prepared as described (13) , and stored frozen (as ≥ 2 mg/ml) at -80 o C. Receptor binding assays − Were made in 1 ml reactions containing 50 mM Hepes-Tris pH 7.4, 0.2 mM EGTA, 0.2 mM DTT, 5 mM MgCl 2 , 10 μM leupeptin, 10 μM bestatin, 0.1 mg/ml bacitracin, 0.1 % (w/v) BSA, and suitable amounts of membrane proteins (0.5-2 μg). [ 125 I] pindolol (50-100,000 cpm) was used as radiotracer. Receptor number (Bmax) was computed from competition binding curves constructed using 12 log-spaced concentrations of unlabeled pindolol. Reaction with MTSEA -MTSEA treatment was performed according to the procedure of Javitch et al. (15), with minor modifications. COS7 cells, plated in T25 flasks or 6-wells plates, were washed 48 hrs after transfection with PBS, and incubated for 2 min at room temperature with freshly prepared MTSEA at the desired final concentrations. The reactions were stopped by aspiration, followed by two washes with ice-cold PBS (the first containing 10 mM cysteine After protein determinations and the collection of aliquots for the analysis of receptor density (see Bmax above), GTPγS binding (measured in quadruplicate) was determined for all membranes in the same experiment. Lower expressed mutants (K, Y, D, I) were tested using 5 μg of protein, while 1 μg of proteins was used for all the others. Data analysis -Apparent equilibrium dissociation constants (K d ) were calculated by non linear fitting of the competition curves according to a fourparameter logistic equation, using the program ALLFIT (16) . Maximal binding capacity (B max ) was calculated by fitting the binding curves with the program LIGAND (17) . The apparent dissociation constants were converted to free energy changes, i.e. ΔG = −ln(1/K d ), given as RT units (R, gas constant, T, absolute temperature). The variation in free energy due to mutation , ΔΔG, was calculated as the difference in binding energy between mutant and wild-type receptor, ΔΔG = ΔG(mut) -ΔG(wt). Energy calculations were computed experiment by experiment before taking averages, so that their 
MATERIALS AND METHODS.

Materials
Comparative modelling of the β 2 -AR and MD
simulations -A molecular model of the human β 2 -AR, truncated at S345, was built by comparative modelling, by means of the MODELLER program (18) , using a modified version of the 2.2 Å X-ray crystal structure of rhodopsin as a template (19) . The general strategy used to select the final structure involved a multistep optimization and refinement process, which is described in detail elsewhere (20) . Briefly, the following steps were carried out: (i) Each of five different templates was used to generate 50 models by randomizing the model coordinates through a random number uniformly distributed in the interval −4/+4 Å. Among the 250 models thus obtained, the three showing the lowest violations of spatial restraints and the highest 3D-Profile scores (Protein Health module in the QUANTA 2000 package (www.accelrys.com)) were selected. In the template used to achieve these models, amino acids 228-245 (3 d intracellular loop) were replaced with the corresponding loop extracted from the computational model of the α 1b -AR (21) , and Q184,C185 (2 d intracellular loop) were deleted.
In addition to the disulphide bridge C106(3.25) − C191, homologous to that present in rhodopsin, a second bridge was also imposed ("special patches" subroutine) between C184 and C190, in accordance with experimental data (22) .
(ii) The selected models, completed by the addition of polar hydrogens, were subjected to automatic and manual rotation of the side chain torsion angles, when in non allowed conformations.
(iii) Next, the models were submitted to extensive energy minimization and molecular dynamics (MD) simulation procedures, essentially as described previously (20) , except that an implicit membranewater model (23) (IMM1), recently implemented in CHARMM (24) , was employed (with the adjustable parameter "a" and the non polar core thickness set as 0.85 and 32 Å, respectively).
(iv) The final input structure, selected on the basis of structural quality checks and degree of similarity to rhodopsin structure, was finally subjected to 1 ns of equilibrated MD simulation. The structures averaged over 1 ns as well as over the first and last 500 ps were considered for the structural analysis.
Numbering of β 2 AR residues -Residues are numbered with two figures. The first is the position in the human β 2 AR sequence. The second, (in parenthesis), is the position relative to the most conserved residue of the helix in the macro alignment of class A GPCRs (25) .
RESULTS.
Validity of the receptor-G s fusion system for the study of the effect of receptor mutations. As shown in fig. 1A , we used membranes from COS cells, transiently transfected with increasing amounts of either G s -fused or wild type receptor vectors to evaluate the fusion protein "specificity" of the guanine nucleotide exchange signal. Net agonist-stimulated GTPase activity and GTPγS binding (not shown) increased with the enhanced expression of fused receptor, but remained close to zero even at very high levels of non fused receptor expression. This confirms that no significant contribution from the interaction of the receptor with endogenous G s can be detected in such read-out (13) . Adenylyl cyclase activity in the same membranes displayed a different pattern. The increased expression of fusion protein resulted in a large enhancement of basal activity, which reflects the increase of Gα s concentration, rather than ligand-independent receptor activity, because identical effects were observed when expressing a fusion protein made between opioid delta receptor and Gα s (not shown). Moreover, ligand-induced enhancement of adenylyl cyclase was not linear and reached saturation at relatively low levels of fusion protein expression (Fig.1B) . Thus, the tethered receptor-Gα system provide quantitative information on ligand-induced receptor activation only if the measured end-point is direct G protein activation, not effector-mediated signalling.
The binding of GTPγS increased linearly with the number of adrenergic binding sites both in the presence and absence and of a maximal agonist concentration (Fig.1, C,D) . The net difference was a linear function of fusion protein expression ( Fig. 1 C,D, insets) with zero intercept and a dimensionless slope, which represents a quantitative estimate of the agonist power to activate the system (intrinsic activity). This value, called maximal exchange index (MEI), is independent of expression level. Thus, by taking the ratio: net pmol/mg of stimulated GTPγS binding vs. net pmol/mg of expressed receptor, we can compare the ability of ligands to maximally activate receptors across membranes expressing different levels of mutants. The enhancement of [
35 S]GTPγS binding was insensitive to pertussis toxin, but markedly reduced by cholera toxin treatment (data not shown), indicating lack of interferences from endogenous G i/o proteins. In addition, the typical pattern of ligand intrinsic activities for the β 2 AR was maintained in the fusion protein construct. In fact, isoproterenol (ISO) and epinephrine (EPI) displayed greater intrinsic activity than dobutamine and halostachin (MAPE), whereas dichloroisoproterenol (DCI) behaved as a weak partial agonist ( fig.2A ).
Ligand binding affinity for the receptor mutants
To evaluate the binding affinity of β 2 AR-Gα s mutants correctly, the recombinant protein must be expressed to a level at least 10-fold greater than that of the endogenous β 2 AR in the host cells, (which, in COS cell lines, can range between 0.05-0.2 pmol/mg of membrane proteins). All residue substitutions, but R207, resulted in receptors that met such criterion. The S207R mutant was thus excluded from the rest of the study. Fig.2B reports a summary of the expression levels recorded through this investigation (data are normalized to the level of expression of the wild-type construct, which was always determined in each experiment). The differences of expression among mutations ranged from 0.3 (S207K) to 2.1 fold (S207G) the wild-type. Whether such diversity may reflect differences in receptor stability or folding efficiency was not investigated in this study.
The binding affinities of the ligands, ISO, EPI, MAPE, and pindolol (PIN) for all mutants are listed as logarithms of the apparent dissociation constants in Table 1 . To visualize the relative potency of each mutated residue to shift binding affinity with respect to wild type receptor, we also plot the data as ΔΔG changes (i.e., ΔG mutant minus ΔG wild-type) for each ligand, ranked according to the magnitude of the residue effect ( fig. 3 ). The most prominent finding of this analysis is that the changes in binding affinity produced by the mutations are ligandspecific.
EPI and ISO, both full agonists with catechol rings, displayed the closest patterns. All mutations produced a loss of binding affinity for such ligands, but the extent of reduction varied greatly. Residues such as E, P, and Q, produced the largest diminutions, (with some differences between EPI and ISO in the relative effects of P and Q). T, H and G produced the smallest decrease. Other than noting that T (the most conservative replacement for the wild-type S) produced the smallest decrease of binding affinity, there was no obvious relationship between the residue ability to be H-bond donor/acceptor and its effect on binding affinity.
The changes of binding affinity for the non catecholic partial agonist MAPE was quite different from that observed for the two catecholamines. Both enhancements and reductions in binding affinity were observed, and the largest changes were not produced by the same residues that mostly affected catecholamines. The aliphatic residues V and I maximally enhanced binding affinity, while N, Q and K produced marked reductions. Unlike that of catecholamines, the affinity of MAPE was only slightly changed by E and P replacements.
A still different pattern was observed for the antagonist PIN. Many residues produced little change or slight increases of binding affinity, but significant diminutions were caused by K and P mutations (Fig. 3) .
Shifts of ligand-induced receptor activation.
To measure how mutations altered the intrinsic ability ligands to activate the receptor, we determined maximal exchange indexes (see Materials and Methods) for EPI, ISO, MAPE, and the weak partial agonist dichloroisoproterenol (DCI), in numerous transfection experiments performed both in COS-7 and HEK293. The data, normalized with respect to the activation observed in the wild-type construct, are shown in fig. 4 .
ISO and EPI were again affected in a similar fashion. Many residues caused loss of ligand induced activation, most effectively L, which produced an essentially inactive receptor, and, next in rank, M, P, N, E, all of which resulted in ≤ 20% of the activation observed in wild-type. Surprisingly, some residues improved agonistinduced receptor activation, particularly D and H, the latter resulting in up to 2-fold enhancement of agonist-mediated G s activation. As observed for binding affinity, no obvious relationship between amino acid property and effect on activation is evident. For example, H and D that bear opposite charges, can both potentiate receptor activation, while E (a conserved replacement for D) results in marked loss of activation. Likewise, the closely related isomers I and L produced divergent effects, improving and abolishing, respectively, catecholamine-induced maximal activation.
The pattern of effects on the receptor activation induced by MAPE displayed both similarities and differences with respect to catecholamines. Marked reductions, roughly similar to those produced on the activation index of EPI and ISO, were caused by N, L, E and Y. Also P diminished activation, but to a much smaller extent than for catecholamines. The two charged residues H and D, did not enhance, but significantly reduced MAPE-induced activation. Also at variance with catecholamines, aliphatic residues such as V, I, and to a lesser extent A, were the most effective in generating improvement of MAPE-induced activation compared to wild type receptor ( fig. 4) .
Although the overall pattern of effects on the activation induced by DCI resembles more closely that observed for MAPE than for catecholamines, a number of DCI-specific changes were noted. V and A, but also K, produced enhancement of activation, while I did little or nothing. As observed for MAPE, the charged residues H and D did not enhance, but diminished DCI-induced activation ( fig. 4) .
Relation between affinity and activity, and correlations with physicochemical descriptors of amino acids.
The relationship between shifts in ligand-induced activation and shifts in binding affinity produced by the 18 mutations for the three ligands EPI, ISO and MAPE is shown in fig. 5 . As evident from the dispersion of the data points, no significant correlation between binding and activation was found for ISO or EPI ( fig. 5 A,B) . A weak (r = 0.62), albeit statistically significant (P < 0.01), correlation coefficient was measured for MAPE ( fig.  5C ). We note, however, that the significance of such correlation is critically dependent on the two residues V and I, which for MAPE enhance both binding affinity and G protein activation. Their omission from the data set abolished the significance of the correlation.
The plots in fig. 5 also serve as a "fingerprint" of the ligand-specific manner by which the series of point mutations in position 5.46 alter receptor properties. Apart from the obvious difference between MAPE and the two catecholamines, subtle divergences between ISO and EPI can also be appreciated. For example residues such as Q, P, and K affect binding and activity differently for the two ligands.
We also searched possible relationships between the effects on binding/activity of the studied ligands and the chemical properties of the replaced amino acids. Up to 78 compilations of physicochemical properties of natural amino acids were considered, including hydrophobicity parameters, size, volume and surface area descriptors, solvation properties, R values, polarity and polarizability indices (26) . Correlations were analyzed between the all the amino acid descriptors and the receptor functional data presented above, (comprising the effect of residues on the shifts of affinity and activity for all the studied ligands, and the changes in receptor expression). None of the estimated correlation coefficients exceeded a value of 0.7. However, some correlations were statistically significant. An extract of the correlation matrix including coefficients reaching the 99% probability level is reported in table 2.
The shift of MAPE affinity was correlated with several hydrophobicity scales, and the shift in MAPE-mediated receptor activation with the propensity of the residue to be buried in a folded protein. Thus the hydrophobicity of the side-chain may be a contributing component for the effects of the mutations on the interaction MAPE/receptor, but plays no role for the other ligands. There were also negative correlations between changes in receptor expression and several measures of residue size, such as bulkiness, surface area, molecular and Van der Waals volumes, indicating that the size of residue 207(5.46) disturbs either receptor folding or stability, which is more likely for a residue holding an inter-helical position. The change in receptor expression levels, however, did not correlate with any of the other receptor binding and functional parameters, which confirms that the determination of such properties is independent of the differences in the membrane concentration of the expressed constructs.
Finally, significant correlations were found between the shift in binding affinity of catecholamines and some amino acid chromatographic properties, related to the propensity to be eluted from silica or cellulose by acidic alcohol:water mixtures (table 2). Although of unclear significance, it is intriguing to find that only the affinity shift for catecholic ligands shows such a relationship.
Changes of receptor constitutive activity.
When increasing levels of a fusion protein are expressed in the membrane, there must be elevation (fig. 6 ). The experimental error was still large enough to prevent the identification of mutations that may diminish constitutive activity or to allow a reliable quantification of the rank order of potency in enhancing it. Yet, a few mutants with clear-cut enhancements of constitutive activity were found. The I207 mutant, displaying the highest level of ligand-independent activity, was further characterized.
A Gα s -tethered version of the original β 2 AR constitutive active mutant (CAM), which carries four amino acid replacements in the C-terminal portion of the 3d intracellular loop (27), was used as reference. The extent of activation of S207I was roughly 60-70% that of the CAM mutation when the two receptors were examined in paired transfections ( fig.7A) . In both receptors, we also assessed the degree of exposure of Cys-285 to a membraneimpermeant methanethiosulfonate analogue, to evaluate the degree of conformational change induced by constitutive activation (15). The extent of MTSEA reactivity in S207I was about 50% that of CAM ( fig.7B ). Thus, both functional and conformational evidences indicate that I207 enhance the constitutive activity of the receptor, to an extent ranging 0.5-0.7 fold that produced by multiple mutations of the third intracellular loop.
Changes of ligand intrinsic activity.
Mutations that affect differently the activation by catecholic and non catecholic ligands may change the pattern of ligand efficacies for the receptor. We searched a single parameter that could accurately rank residues for their power to induce switches of efficacy. A good descriptor proved to be the net difference in normalized maximal exchange indices between pairs of ligand. Near-to-zero values indicate no change, whereas positive or negative values denote a switch of intrinsic activity in favour, respectively, of the first or the second ligand of the examined pair. Such differences between EPI and ISO were close to zero for all residues (Fig. 8A) , demonstrating that none of the 18 mutations substantially alter the relative power of the two catecholamines (both full agonists) to activate the receptor. Thus, either can be equivalently used to analyze the difference with the other ligands.
MEI differences between EPI vs. MAPE ( fig.  8B ) and EPI vs. DCI ( fig. 8C) , identify a number of mutants in which switches of maximal activation are evident. D and H, enhanced the maximal stimulations induced by catecholamine and concurrently reduced those induced by both MAPE and DCI, indicating that such receptors have lost the ability to respond to partial agonists. In contrast, I, V, K, and A caused a somewhat opposite switch, by enhancing the effect of the partial agonists compared to the catecholamines. While K and V enhanced the stimulation of both DCI and MAPE, A and I only affected the first and the second respectively ( fig. 8BC) .
Concentration response curves for ligandinduced stimulation of GTPγS binding by EPI, MAPE and DCI were compared in the wild-type receptor and in the 5 mutants visualized in such analysis, D, H, I, V, K. The data, normalized to the effect produced by 100 μM ISO ( fig. 9A ), confirm that in this subset of mutations there are extensive changes in the pattern of ligand efficacies.
In D and H mutants the relative intrinsic activity of MAPE (0.7-0.8 in wild-type) was reduced to 0.2 and 0.12, respectively, and that of the weaker partial agonist DCI (0.3-0.4 in wild-type), to < 0.04. Consequently, DCI became a pure competitive antagonist in the H mutant, as indicated by its ability to produce a parallel shift to the concentrationresponse curve for ISO ( fig. 9B ). Such receptors are hyper-activated by full agonists and poorly activated by partial agonists.
In contrast, the aliphatic residues I and V caused an inversion in the intrinsic activity of adrenergic ligands. The relative effect of MAPE was raised to 1.3 and 1.7 by I and V, respectively, which makes this ligand the full agonist and catecholamines only partial agonists in such receptors. V replacement also greatly enhanced the relative intrinsic activity of DCI (0.84 relative to ISO), but the I mutation did not so (0.19). A similar, yet not identical, phenotype was generated by the K mutation. In this receptor the intrinsic activities of DCI and MAPE were raised to the same level of ISO and EPI, so that all ligands appear as equally effective full agonists ( fig.  9A ).
Study of H5 serines orientation in wild-type β 2 AR by
SCAM and computational modeling. We used three β 2 AR mutants carrying single Cys substitutions of the serines in H5 (7) to evaluate the relative accessibility of the residues by the substituted cysteine accessibility method (28) . Fig.  10A shows that MTSEA at micromolar concentrations efficiently blocked ligand binding for S203C and S204C mutants, but up to 1 mM did nothing for S207C where a small 20% inhibition was only observed at 5 mM. This indicates that the residue 5.46 is far less exposed than the others to the polar core of the receptor. Results of molecular modelling of the β 2 AR over a rhodopsin template followed by extended MD simulations were in partial agreement with such findings. In the averaged structure, which is representative of the most recurrent configurations collected in this study ( fig. 10B ), S203(5.42) was clearly exposed towards the binding crevice, while S207(5.46) pointed towards H3 at H-bond compatible distance from T118(3.37). However, also S204(5.43) displayed, on average, an interhelical orientation, pointing towards H6, where it might interact with N293(6.55). Interestingly, the analysis of the different MD trajectories generated in this study reveals that the stretch of residues 202-212 (comprising the serine cluster) is highly dynamic. Bulge-like deformations and local unwinding in this area were often observed, and made S5.43 more oriented versus the binding crevice, while S5.46 remained inter-helical. Such situation, which is infrequent in the empty receptor, became more common in the EPI-bound form (results not shown). It is thus possible that the topology of S5.43 is altered by MTSEA entry, possibly via an interaction of its amino-tail with D113(3.32). That could account for the discrepancy between SCAM results and the empty receptor configuration.
DISCUSSION.
In this study we replaced S207(5.46) in H5 of the human β 2 AR with all other natural amino acids and analyzed the effect of such mutations on binding affinity and efficacy of a number of adrenergic ligands. The results of this work raise 3 issues that deserve further discussion.
The role of S207(5.46) in the β 2 AR.
We may expect that all amino acids replacement of a serine residue which is exposed to the β 2 AR binding cleft and is primarily involved in H-O H-bonds with catechol hydroxyls, may decrease catecholamine affinity via two overlapping mechanisms. One is loss of the H-bond between the receptor and the ligand, which should predominantly affect the affinity of ligands with a catechol ring. The second, expected instead to affect all ligands (including antagonists and analogues lacking a catechol ring), might be steric hindrance that bulky side-chains would exert on the ligand's ability to enter the binding crevice. Such effect should be more severe, the greater the size of the replaced residue. As shown here, the pattern of effects produced by all-residue substitution of S207(5.46) is far more complex than what envisioned above. Although catecholamines were indeed affected to a larger extent than other ligands, the observed changes in binding affinities were neither consistent with the mere loss of a ligandreceptor docking interaction, nor with a sizedependent obstruction of ligand entry.
The total span of free energy changes produced by the replacement of serine with the 18 residues ranged from 4.5 (ISO) to 6 (EPI) RT-units (equivalent to 11−15 kJ/mol at 25 o C, respectively) for catecholamines, and from 3.4 (MAPE) to 4 (PIN) RT-units (i.e. 8−10 kJ/mol) for non catecholic ligands. Since MAPE and PIN cannot form Hbonding with S207(5.46), we suggest that only the difference between the two sets of ranges, i.e. 1−2 RT-units (2.5-5 kJ/mol), might be attributed to the loss of a putative intermolecular bond between S207(5.46) and the ligand. This is a least estimate, for contributions from hydrophobic effects, side chain entropy, and, possibly, water intrusion into "cavities" opened by non isosteric mutations, can heavily affect the ΔΔG values derived from mutagenesis. Despite the uncertainty, such a small value tells that a great part of energy change that we measure in response to the set of mutations may result from conformational perturbations in the receptor, rather than from the loss of a ligand interaction with a binding subsite.
We also note that the relationship between sidechain identity and change of binding energy for the 4 ligands is not consistent with the presence of a size-dependent clash between the side-chain projecting in the binding cleft and ligand entry. In fact, side-chains bulkier than S, either left unchanged (W), or actually enhanced (I, Y) the binding affinity for MAPE, whereas quasi-isosteric changes (C, A) reduced catecholamine affinity to a larger extent than what the bulkiest residues (i.e. F, Y and W) actually did. Pro, the side chain which caused the largest decrease of affinity for 3 out of 4 ligands, is not bulky, but a well-known perturbator of α-helix orientation. Finally, there were no significant correlations between the ΔΔG of the 4 ligands and a variety of indicators of side-chain size, including calculated volume, area, bulkiness, Van der Waal size, partial molar volumes. Such correlations were instead evident for the residueinduced change in receptor expression.
Such observations, taken collectively, raises the question as to whether S207(5.46) projects toward the internal crevice or is it rather concealed within the inter-helical interface of H5. MD simulations on empty β 2 AR model indicate that S207(5.46) is the residue most frequently directed towards H3 and involved in H-bonding interactions with T118(3.37). This is consistent with the knowledge that Ser/Thr residues arranged in SxxSS or SxxxS motifs, particularly if associated to a P in i+4 position, are capable to drive strong association between transmembrane helices (12) . The prediction that positions 5.46 and 3.37 in β 2 AR are engaged in Hbonding interactions is consistent with rhodopsin structure, where the equivalent positions are respectively occupied by H-bonding linked histidine and glutamate (22, 29) . In addition, using SCAM (28), we found that C203(5.42) and C204(5.43) are far more reactive than C207(5.46), which indicates that the side-chain 5.46 is less accessible from the polar cleft than the others in the resting form of the receptor.
All the above considerations cast doubts on the otherwise widespread notion that S207(5.46) is available for the formation of a direct H-bond with catecholamines.
One plausible explanation is that S207(5.46) becomes available for ligand docking only during the dynamics of ligand entry. We reported a strong cooperativity between mutation of each of the three H5 serines and changes of the catecholamine structure that affect contacts at other sites of the receptor (7) . That suggests the existence of an "induced fit" mechanism in catecholamine binding, so that initial contacts between ligand and receptor synergistically induce the exposure of additional docking points. Thus, the S207(5.46) side-chain may turn and interact with the ligand only after initial interactions between the ligand and other subsites of the receptor are established. If so, the residue would not be detectable by the cysteine accessibility method, because the thiol reagent enters the cleft without interacting with the receptor subsites that trigger its exposure. This mechanism agrees with the multistep kinetics of catecholaminereceptor interactions observed in fluorophor labelled β 2 AR (8). Recent molecular dynamics simulations of the 5HT 1A receptor in empty and agonist bound form suggest a similar mechanism (20) . Only after the "primary" interactions with D3.32 and S5.42 are established, serotonin is found to form additional "secondary" interactions with residues in H6 (F6.51) and H5 (T5.43), which occur concurrently with the maximal destabilization of the salt bridges involving the DRY arginine in the cytosolic extension of H3 -a hallmark of receptor activation (20) . Thus, a step-wise agonist binding process might be the general feature of all amine GPCRs, and play a crucial role in the process of agonistinduced activation.
Helix-5 can trigger different modes of receptor activation.
Regardless of the orientation of S207(5.46) in wild type receptor, the substitution of this residue by all natural amino acids has vast effects on the process of receptor activation. Four main receptor phenotypes were generated by mutagenesis. Peculiar of the data is the simultaneous occurrence of two opposite trends. Very similar side chains produced large functional differences, whereas unrelated residues caused equivalent functional outputs. Examples of the first case are the pairs I and L (the first causing constitutive activation, and the second total inactivation), or D and E (inducing, respectively, enhanced catecholamine responsiveness and inactivation). Examples of the second case, are H and D (both enhancing receptor activation), or K and I, (both producing constitutive activation). A detailed molecular modelling of the 18 receptor mutants is under way, and hopefully may bring more insight. One challenging question is how small structural variations, (e.g. the change from I to L side chain), can make the difference between constitutive activation and full inactivation.
Although not allowing to draw a precise molecular mechanism, our results clearly suggest that there are at least two alternative pathways that link perturbations in position 5.46 to the molecular changes underlying the active form of the receptor.
One is represented by the replacement of the two polar residues, H and D, which dramatically enhance the activation induced by catecholamines and suppress that mediated by non catecholic ligands, with no enhancement of constitutive activity. The other is the substitutions with the aliphatic residues, V, I and A, or the charged residue K, all of which magnify the activation induced by non catecholic partial agonists, and half of which also produce ligand-independent activation. This has two interesting implications.
One is that catecholic and non catecholic agonists may activate the wild type receptor by different mechanisms, thus, the two groups of mutations may reflect changes that preferentially facilitate either one or the other type of process. Hints on the molecular basis of such differences come from studies on rhodopsin. Solid-phase NMR analysis of the dark and light-activated rhodopsin forms shows that retinal translation towards H5 in the region of H211(5.46) may be a first move for light-induced conformational changes (30) . Enhanced ligand contacts in this area of H5 would break the inter-helical interactions between H3-H5, and move this helix into an active conformation. It was suggested that such mechanism may be general for all class-A receptors, including β 2 AR. This is in line with the hypothesis that S207(5.46) forms a helix-ligand contact only after the motion generated by initial catecholamine interactions with subsites in H3, H6, and, possibly, S5.42 in H5. This "induced" S207(5.46) contact may boost or modify the consequences of the ligand's interaction with H6, where rigid body movement and outward rotation of the helix are known to be key elements of activation (20, (30) (31) (32) . The conditional exposure of Ser 5.46 would also be consistent with the induced fit mechanism (7) and the multistep activation kinetics (8) of catecholamines discussed above. In contrast, non catechol partial agonists, lacking the S207(5.46) interaction, must be inducing H6 motion without the additional connection with H5, which is likely to result in a different type of motion of this helix relative to the others.
A second implication is that constitutive receptor activity and agonist-dependent activation can originate from different structural changes, and therefore do not reflect identical receptor forms.
In fact, among the 4 mutations that enhanced partial agonist effects, at least two also produced ligand-independent activity. Therefore, the constitutively active receptor form shares more similarities with that bound to a partial agonist than that bound to a full agonist. If so, we may suggest a fundamental difference in the way partial and full agonists activate receptors. While the partial agonist might simply be a "catalyst" of the intrinsic constitutive activity restrained within the unbound receptor form, the full agonist may act differently, generating a 'new' highly dynamic form of the receptor, which substantially differs from the active configurations that the receptor infrequently explores in the unbound state.
Differences between partial and full agonism.
Ligands that bind to a G protein coupled receptor (GPCR) display wide variations in their power to trigger receptor activation. This intrinsic ligand/receptor property, known as efficacy (33), ranges from full agonism to inverse agonism. Differences in efficacy are usually attributed to the variable extent to which a ligand can induce an optimal receptor configuration for G protein activation. Although it is likely that each ligand generates on binding a unique receptor conformation, a common subset of perturbations that are relevant to G protein activation are thought to be shared to variable degrees by different ligands, which results in different grades of receptor activation. Thus, efficacy is viewed as a continuous gradient of changes in the active configuration of the receptor which seamlessly occur within other physical modifications induced by ligand binding, and reaches the top at the full agonism level. Consequently, affinity and efficacy often appear as properties that have independent and distinct structural requirements (34) .
Our data prospect two interesting deductions, on such matter.
First, the observations that point mutations in a residue of the agonist binding pocket can either switch the full agonist into a partial one, or do the reverse, suggest that full and partial agonists activate the receptor via qualitatively different mechanisms. In fact they easily diverge as even the most subtle modification alters the stereochemistry of ligand-receptor interactions. Similar conclusions were reached from the comparison of the relation between GTP-shift on binding and GTPase activation in a series of β 2 AR agonists (35) and from the analysis of fluorescence lifetime distributions of fluorophor-labeled β 2 AR bound to different agonists (36) .
Second, the findings that some mutations can enhance the extent of G protein activation induced by catecholamines indicate that the active configuration triggered by full agonist binding does not constitute the up most level of receptor activation. Larger effects are in fact possible with certain modifications of residue 5.46.
The "hyperactive" mutants H and D, although displaying a greater level of activation than wild type receptor, bind full agonists with reduced affinity. Therefore, at lower agonist concentrations they respond far less than a wild type receptor. Thus, it appears that the configuration of the active "full agonist form" is not the one having the greatest level of activation, but is one optimized to achieve the best activation with the best binding affinity for the natural ligand. Such outcome, perhaps resulting from the step-wise dynamics of the full agonist interaction with the receptor, implies a perfect match between ligand structure and receptor structure, which cannot be emulated by mutations that enhance the intrinsic constitutive activity of the receptor. 
